Access count of this item: 135

Files in This Item:
File Description SizeFormat 
24_0879.pdf590.45 kBAdobe PDFView/Open
Title: 前立腺癌に対するEstramutine Phosphate(Estracyt)の効果
Authors: 片山, 喬  KAKEN_name
島崎, 淳  KAKEN_name
大塚, 薫  KAKEN_name
脇坂, 正美  KAKEN_name
石川, 堯夫  KAKEN_name
中山, 朝行  KAKEN_name
真鍋, 溥  KAKEN_name
相川, 英男  KAKEN_name
村上, 信乃  KAKEN_name
Author's alias: Katayama, Takashi
Shimazaki, Jun
Otsuka, Kaoru
Wakisaka, Masami
Ishikawa, Takao
Nakayama, Yomoyuki
Manabe, Hiroshi
Aikawa, Hideo
Murakami, Shino
Issue Date: Oct-1978
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 24
Issue: 10
Start page: 879
End page: 888
Abstract: Estramustine phosphate (Estracyt) was administered per os to 23 patients with carcinoma of the prostate and its therapeutic effect was investigated. The following results were obtained. 1. Group I consisting of 13 cases without previous treatment showed good response in all. 2. Group II consisting of 10 cases resistant to the hormone therapy showed response in 30% of them. 3. There was an obvious difference between Group I and II in the improvement of general condition, subjective symptoms, amount of residual urine, anemia, acid and alkaline phosphatase level, local findings, metastatic lesions and urethrographic findings. For example, urethrographic improvement was obtained in 83.3% of Group I cases and 25.0% of Group II cases. 4. Of side effects, the most frequently seen was that of the breast. Others were also related with the estrogenic effect. The side effects upon the liver and hemic system must be considered. 5. Estracyt is a useful drug for carcinoma of the prostate not only in previously untreated cases but in hormone-resistant cases. It is, however, uneffective for the advanced cases. Choice of the cases is therefore important.
Appears in Collections:Vol.24 No.10

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.